One of my classmates recently returned from Afghanistan and brought to my attention a drug they have been using over there in the ANA hospitals, which is also being carried by the Special Forces medics who may be further removed from trauma care. It is a fibrinolysis inhibitor, but I don't think they really know how it works. You can download the study free from the Lancet, July 2010.
Is anyone out there using Tranexamic acid or Aminocaproic acid in their prehospital protocols, or considering it? The recent CRASH2 study provides some interesting data to consider. I'm only now finding out about it. Of course, I have no financial interest in it or the manufacturer.
BLUF: Randomized double blind controlled multicenter international trial of tranexamic acid (TXA) in 20,000 trauma patients from 274 patients in 40 countries.
Given as a single 1g dose, followed by an additional 1g over 8 hours.
Patients who "clearly needed" it were not randomized, nor were patients who had clear contraindications.
10% reduction in all-cause mortality
15% reduction in mortality from hemorrhage
No significant differences in blood units given, or number of surgeries
Trend toward benefit when given earlier after injury
Hospital-based protocol, not prehospital
No increase in vascular occlusive events such as CVA, MI, PE, or DVT.
Shelf stable at room temperature, $9 per dose
It's a hell of a lot cheaper than rFactor VIIa.
'zilla